Company Overview
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.
Key Financial Figures
For the year ended December 31, 2025, DiaMedica reported $0 in revenue. The company’s basic and diluted net loss per share (EPS) was $(0.70). Overall net loss for the year totaled $32.76 million.
Additional Financial Insights
Research and development expenses increased to $24.61 million, primarily supporting the continuation of clinical trials. DiaMedica concluded the year with $59.9 million in cash and short-term investments. Management anticipates this capital will be sufficient to fund operations through the second half of 2027.
The post DiaMedica Therapeutics 2025 Financial Review first appeared on Alphastreet.
